These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 37789230)
1. Identification by molecular dynamic simulation and in vitro validation of SISB-A1, N-[1-(4-bromophenyl)-3-methyl-1H-pyrazol-5-yl]-2-[(2-oxo-4-phenyl-2H-chromen-7-yl) oxy], as an inhibitor of the Abl Al Shahrani M; Gahtani RM; Abohassan M; Alasmari S; Makkawi M Med Oncol; 2023 Oct; 40(11):316. PubMed ID: 37789230 [TBL] [Abstract][Full Text] [Related]
2. Discovery of 3-((3-amino- El-Damasy AK; Kim HJ; Park JW; Nam Y; Hur W; Bang EK; Keum G J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2228515. PubMed ID: 37470410 [TBL] [Abstract][Full Text] [Related]
3. MPT0B002, a novel microtubule inhibitor, downregulates T315I mutant Bcr-Abl and induces apoptosis of imatinib-resistant chronic myeloid leukemia cells. Yeh YY; Liou JP; Lee YL; Lin JY; Huang HM Invest New Drugs; 2017 Aug; 35(4):427-435. PubMed ID: 28349229 [TBL] [Abstract][Full Text] [Related]
4. PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia. Gupta P; Kathawala RJ; Wei L; Wang F; Wang X; Druker BJ; Fu LW; Chen ZS Cancer Lett; 2016 Dec; 383(2):220-229. PubMed ID: 27720778 [TBL] [Abstract][Full Text] [Related]
5. Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML). Lu T; Cao J; Zou F; Li X; Wang A; Wang W; Liang H; Liu Q; Hu C; Chen C; Hu Z; Wang W; Li L; Ge J; Shen Y; Ren T; Liu J; Xia R; Liu Q Eur J Pharmacol; 2021 Apr; 897():173944. PubMed ID: 33581133 [TBL] [Abstract][Full Text] [Related]
6. Preclinical development of a novel BCR-ABL T315I inhibitor against chronic myeloid leukemia. Gupta P; Zhang GN; Barbuti AM; Zhang X; Karadkhelkar N; Zhou J; Ding K; Pan J; Yoganathan S; Yang DH; Chen ZS Cancer Lett; 2020 Mar; 472():132-141. PubMed ID: 31837444 [TBL] [Abstract][Full Text] [Related]
7. Anthelmintic niclosamide suppresses transcription of BCR-ABL fusion oncogene via disabling Sp1 and induces apoptosis in imatinib-resistant CML cells harboring T315I mutant. Jin B; Wang C; Shen Y; Pan J Cell Death Dis; 2018 Jan; 9(2):68. PubMed ID: 29358661 [TBL] [Abstract][Full Text] [Related]
8. Discovery of (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)propanamide (CHMFL-ABL-121) as a highly potent ABL kinase inhibitor capable of overcoming a variety of ABL mutants including T315I for chronic myeloid leukemia. Liu X; Wang B; Chen C; Jiang Z; Hu C; Wu H; Zhang Y; Liu X; Wang W; Wang J; Hu Z; Wang A; Huang T; Liu Q; Wang W; Wang L; Wang W; Ren T; Li L; Xia R; Ge J; Liu Q; Liu J Eur J Med Chem; 2018 Dec; 160():61-81. PubMed ID: 30317026 [TBL] [Abstract][Full Text] [Related]
9. BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome. Elias MH; Baba AA; Azlan H; Rosline H; Sim GA; Padmini M; Fadilah SA; Ankathil R Leuk Res; 2014 Apr; 38(4):454-9. PubMed ID: 24456693 [TBL] [Abstract][Full Text] [Related]
10. Discovery of a Candidate Containing an ( Zhang D; Li P; Gao Y; Song Y; Zhu Y; Su H; Yang B; Li L; Li G; Gong N; Lu Y; Shao H; Yu C; Huang H J Med Chem; 2021 Jun; 64(11):7434-7452. PubMed ID: 34011155 [TBL] [Abstract][Full Text] [Related]
11. Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-kappaB signaling and depleting Bcr-Abl. Lu Z; Jin Y; Chen C; Li J; Cao Q; Pan J Mol Cancer; 2010 May; 9():112. PubMed ID: 20482842 [TBL] [Abstract][Full Text] [Related]
12. HS-543 induces apoptosis of Imatinib-resistant chronic myelogenous leukemia with T315I mutation. Kim SJ; Jung KH; Yan HH; Son MK; Fang Z; Ryu YL; Lee H; Lim JH; Suh JK; Kim J; Lee S; Hong S; Hong SS Oncotarget; 2015 Jan; 6(3):1507-18. PubMed ID: 25483100 [TBL] [Abstract][Full Text] [Related]
13. The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile. Eide CA; Adrian LT; Tyner JW; Mac Partlin M; Anderson DJ; Wise SC; Smith BD; Petillo PA; Flynn DL; Deininger MW; O'Hare T; Druker BJ Cancer Res; 2011 May; 71(9):3189-95. PubMed ID: 21505103 [TBL] [Abstract][Full Text] [Related]
14. Prevalence of BCR-ABL T315I Mutation in Malaysian Patients with Imatinib-Resistant Chronic Myeloid Leukemia. Mat Yusoff Y; Abu Seman Z; Othman N; Kamaluddin NR; Esa E; Zulkiply NA; Abdullah J; Zakaria Z Asian Pac J Cancer Prev; 2018 Dec; 19(12):3317-3320. PubMed ID: 30583336 [TBL] [Abstract][Full Text] [Related]
15. Curcumin derivative C817 inhibits proliferation of imatinib-resistant chronic myeloid leukemia cells with wild-type or mutant Bcr-Abl in vitro. Wu LX; Wu Y; Chen RJ; Liu Y; Huang LS; Lou LG; Zheng ZH; Chen YZ; Xu JH Acta Pharmacol Sin; 2014 Mar; 35(3):401-9. PubMed ID: 24487968 [TBL] [Abstract][Full Text] [Related]
16. CD-200 induces apoptosis and inhibits Bcr-Abl signaling in imatinib-resistant chronic myeloid leukemia with T315I mutation. Fang Z; Jung KH; Yan HH; Kim SJ; Son MK; Rumman M; Lee H; Kim KW; Yoo HD; Hong SS Int J Oncol; 2015 Jul; 47(1):253-61. PubMed ID: 25963192 [TBL] [Abstract][Full Text] [Related]
17. Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment. Oaxaca DM; Yang-Reid SA; Ross JA; Rodriguez G; Staniswalis JG; Kirken RA Tumour Biol; 2016 Sep; 37(9):12643-12654. PubMed ID: 27444277 [TBL] [Abstract][Full Text] [Related]
18. HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia. Yun SM; Jung KH; Kim SJ; Fang Z; Son MK; Yan HH; Lee H; Kim J; Shin S; Hong S; Hong SS Cancer Lett; 2014 Jun; 348(1-2):50-60. PubMed ID: 24657654 [TBL] [Abstract][Full Text] [Related]
19. Metabolic characterization of imatinib-resistant BCR-ABL T315I chronic myeloid leukemia cells indicates down-regulation of glycolytic pathway and low ROS production. Ko BW; Han J; Heo JY; Jang Y; Kim SJ; Kim J; Lee MJ; Ryu MJ; Song IC; Jo YS; Kweon GR Leuk Lymphoma; 2016 Sep; 57(9):2180-8. PubMed ID: 26854822 [TBL] [Abstract][Full Text] [Related]
20. In silico design and computational evaluation of novel 2-arylaminopyrimidine-based compounds as potential multi-targeted protein kinase inhibitors: application for the native and mutant (T315I) Bcr-Abl tyrosine kinase. Koroleva EV; Kornoushenko YV; Karpenko AD; Bosko IP; Siniutsich JV; Ignatovich ZV; Andrianov AM J Biomol Struct Dyn; 2023 Jun; 41(9):4065-4080. PubMed ID: 35470777 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]